KR20240139600A - 완전 갯과 항-갯과 pd-1 항체 및 이의 용도 - Google Patents

완전 갯과 항-갯과 pd-1 항체 및 이의 용도 Download PDF

Info

Publication number
KR20240139600A
KR20240139600A KR1020247022132A KR20247022132A KR20240139600A KR 20240139600 A KR20240139600 A KR 20240139600A KR 1020247022132 A KR1020247022132 A KR 1020247022132A KR 20247022132 A KR20247022132 A KR 20247022132A KR 20240139600 A KR20240139600 A KR 20240139600A
Authority
KR
South Korea
Prior art keywords
antibody
antigen
acid sequence
amino acid
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022132A
Other languages
English (en)
Korean (ko)
Inventor
도날드 엘. 시겔
니콜라 제이. 메이슨
니콜라스 체스터
케렌 파즈
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20240139600A publication Critical patent/KR20240139600A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247022132A 2021-12-10 2022-12-09 완전 갯과 항-갯과 pd-1 항체 및 이의 용도 Pending KR20240139600A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288284P 2021-12-10 2021-12-10
US63/288,284 2021-12-10
PCT/US2022/081297 WO2023108138A1 (en) 2021-12-10 2022-12-09 Fully canine anti-canine pd-1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20240139600A true KR20240139600A (ko) 2024-09-23

Family

ID=86731339

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247022132A Pending KR20240139600A (ko) 2021-12-10 2022-12-09 완전 갯과 항-갯과 pd-1 항체 및 이의 용도

Country Status (7)

Country Link
US (1) US20250051447A1 (https=)
EP (1) EP4444754A4 (https=)
JP (1) JP2025503400A (https=)
KR (1) KR20240139600A (https=)
CN (1) CN118922441A (https=)
CA (1) CA3240188A1 (https=)
WO (1) WO2023108138A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106547A1 (en) * 2023-11-14 2025-05-22 The Trustees Of Dartmouth College Anti-canine pd-1 antibodies, compositions containing, and therapeutic or diagnostic use thereof
WO2025113570A1 (en) * 2023-11-29 2025-06-05 Vetigenics, Inc. Fully canine antibodies and uses thereof
CN120137035A (zh) * 2023-12-06 2025-06-13 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
CN106029697B (zh) * 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
SG11202105153RA (en) * 2018-11-19 2021-06-29 Biocytogen Pharmaceuticals Beijing Co Ltd Anti-pd-1 antibodies and uses thereof

Also Published As

Publication number Publication date
EP4444754A4 (en) 2025-12-31
WO2023108138A9 (en) 2024-09-26
EP4444754A1 (en) 2024-10-16
CN118922441A (zh) 2024-11-08
JP2025503400A (ja) 2025-02-04
US20250051447A1 (en) 2025-02-13
CA3240188A1 (en) 2023-06-15
WO2023108138A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
CN114761036B (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
JP2021525080A (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
US20250051447A1 (en) Fully canine anti-canine pd-1 antibodies and uses thereof
CN114805582B (zh) 抗Trop2纳米抗体及其用途
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
WO2020228806A1 (zh) 针对密蛋白18a2的抗体及其应用
KR20210104749A (ko) 예정 사멸 1(pd-1)에 대한 신규한 단일클론성 항체
AU2020363041B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
KR20240158314A (ko) 새로운 면역 조절제의 개발 및 적용
JP7419238B2 (ja) Ｐｄ１結合剤
US12240901B2 (en) Humanized anti-BASIGIN antibodies and the use thereof
WO2022100590A1 (zh) 针对密蛋白18a2的adcc增强型人源化抗体及其应用
TW202115123A (zh) 一種抗ｐｄ－ｌ１抗原結合蛋白及其應用
US20250171541A1 (en) Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
TW202246340A (zh) 抗ctla-4抗體及其應用
WO2025113570A1 (en) Fully canine antibodies and uses thereof
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
HK40089099A (en) Anti-tigit antibody and double antibody and their application
HK40071804A (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000